Dominique Bertrand1, Philippe Gatault2, Maïté Jauréguy3, Cyril Garrouste4, Johnny Sayegh5, Nicolas Bouvier6, Sophie Caillard7, Luca Lanfranco8, Aliénor Galinier9, Charlotte Laurent1, Isabelle Etienne1, Fabienne Farce10, Arnaud François11, Dominique Guerrot1. 1. Nephrology Kidney Transplantation Dialysis, CHU Rouen, Rouen, France. 2. Nephrology Kidney Transplantation, CHU Tours, Tours, France. 3. Nephrology Kidney Transplantation, CHU Amiens, Amiens, France. 4. Nephrology Kidney Transplantation, CHU Clermont Ferrand, Clermont Ferrand, France. 5. Nephrology Kidney Transplantation, CHU Angers, Angers, France. 6. Nephrology Kidney Transplantation, CHU Caen, Caen, France. 7. Nephrology Kidney Transplantation, CHU Strasbourg, Strasbourg, France. 8. Nephrology Kidney Transplantation, CHU Brest, Brest, France. 9. Nephrology Kidney Transplantation, CHU Poitiers, Poitiers, France. 10. EFS Normandie, EFS Normandie, Rouen, France. 11. Pathology, CHU Rouen, Rouen, France.
Abstract
BACKGROUND: De novo donor-specific antibodies (DSAs) are associated with antibody-mediated rejection (AMR) and allograft loss. Whether monitoring of de novo DSA (dnDSA) paired with systematic kidney biopsy should become routine remains to be established. METHODS: A retrospective multicentric study (9 French kidney transplant units of the Spiesser group) included patients without graft dysfunction biopsied because of the presence of dnDSA (One Lambda, mean fluorescence intensity [MFI], >1000). RESULTS: One hundred twenty-three patients (85 male/38 female; mean age, 49.5 ± 13.1 y old) were biopsied after the detection of a dnDSA, 65.3 months (median) after kidney transplantation. Graft function was stable within 3 months before biopsy (estimated glomerular filtration rate, 55.3 ± 18.9 mL/min/1.73 m). Fifty-one subclinical AMRs (sAMRs) (41.4%) were diagnosed, of which 32 (26%) active and 19 (15.5%) chronic active sAMR. Seventy-two biopsies revealed no AMR (58.5%). Predictive factors associated with the diagnosis of active sAMR were MFI of immunodominant DSA >4000, MFI of the sum of DSA >6300, age of the recipient <45 years old, and the absence of steroids at biopsy. The presence of proteinuria >200 mg/g was predictive of chronic active sAMR. The decrease of estimated glomerular filtration rate at 5 years post-biopsy was significantly higher in patients with acute sAMR (-25.2 ± 28.3 mL/min/1.73 m) and graft survival significantly lower. CONCLUSIONS: Performing a kidney graft biopsy for the occurrence of dnDSA without renal dysfunction leads to the diagnosis of a sAMR in over 40% of cases. Nevertheless, we did not observe any effect of standard treatment in acute sAMR.
BACKGROUND: De novo donor-specific antibodies (DSAs) are associated with antibody-mediated rejection (AMR) and allograft loss. Whether monitoring of de novo DSA (dnDSA) paired with systematic kidney biopsy should become routine remains to be established. METHODS: A retrospective multicentric study (9 French kidney transplant units of the Spiesser group) included patients without graft dysfunction biopsied because of the presence of dnDSA (One Lambda, mean fluorescence intensity [MFI], >1000). RESULTS: One hundred twenty-three patients (85 male/38 female; mean age, 49.5 ± 13.1 y old) were biopsied after the detection of a dnDSA, 65.3 months (median) after kidney transplantation. Graft function was stable within 3 months before biopsy (estimated glomerular filtration rate, 55.3 ± 18.9 mL/min/1.73 m). Fifty-one subclinical AMRs (sAMRs) (41.4%) were diagnosed, of which 32 (26%) active and 19 (15.5%) chronic active sAMR. Seventy-two biopsies revealed no AMR (58.5%). Predictive factors associated with the diagnosis of active sAMR were MFI of immunodominant DSA >4000, MFI of the sum of DSA >6300, age of the recipient <45 years old, and the absence of steroids at biopsy. The presence of proteinuria >200 mg/g was predictive of chronic active sAMR. The decrease of estimated glomerular filtration rate at 5 years post-biopsy was significantly higher in patients with acute sAMR (-25.2 ± 28.3 mL/min/1.73 m) and graft survival significantly lower. CONCLUSIONS: Performing a kidney graft biopsy for the occurrence of dnDSA without renal dysfunction leads to the diagnosis of a sAMR in over 40% of cases. Nevertheless, we did not observe any effect of standard treatment in acute sAMR.
Authors: Akhil Sharma; Dana R Jorgensen; Rajil B Mehta; Puneet Sood; Chethan M Puttarajappa; Christine M Wu; Amit D Tevar; Michele Molinari; Adriana Zeevi; Sundaram Hariharan Journal: Transpl Int Date: 2022-03-17 Impact factor: 3.782
Authors: Maria Butiu; Bogdan Obrisca; Lena Sibulesky; Ramasamy Bakthavatsalam; Kelly D Smith; Idoia Gimferrer; Paul Warner; Gener Ismail; Nicolae Leca Journal: Transplant Direct Date: 2022-01-26
Authors: Francesco Guzzi; Luigi Cirillo; Elisa Buti; Francesca Becherucci; Carmela Errichiello; Rosa Maria Roperto; James P Hunter; Paola Romagnani Journal: Int J Mol Sci Date: 2020-09-19 Impact factor: 5.923
Authors: Christoph B Waldecker; Panagiota Zgoura; Felix S Seibert; Sabina Gall; Peter Schenker; Frederic Bauer; Benjamin Rohn; Richard Viebahn; Nina Babel; Timm H Westhoff Journal: J Nephrol Date: 2021-04-17 Impact factor: 3.902